343 related articles for article (PubMed ID: 34900759)
1.
Yu W; Xiong L; Luo Q; Chen Y; Ji J; Ying C; Liu Z; Xiao Y
Front Cell Infect Microbiol; 2021; 11():780365. PubMed ID: 34900759
[TBL] [Abstract][Full Text] [Related]
2. In vitro efficacy of ceftazidime-avibactam, aztreonam-avibactam and other rescue antibiotics against carbapenem-resistant Enterobacterales from the Arabian Peninsula.
Sonnevend Á; Ghazawi A; Darwish D; Barathan G; Hashmey R; Ashraf T; Rizvi TA; Pál T
Int J Infect Dis; 2020 Oct; 99():253-259. PubMed ID: 32738488
[TBL] [Abstract][Full Text] [Related]
3. Effect of ceftazidime-avibactam combined with different antimicrobials against carbapenem-resistant
Wu Y; Yu W; Chu X; Zhang J; Jia P; Liu X; Zhu Y; Xu Y; Yang Q
Microbiol Spectr; 2024 Jun; 12(6):e0010724. PubMed ID: 38712934
[TBL] [Abstract][Full Text] [Related]
4. Optimal treatment of ceftazidime-avibactam and aztreonam-avibactam against bloodstream infections or lower respiratory tract infections caused by extensively drug-resistant or pan drug-resistant (XDR/PDR)
Kang Y; Xie L; Yang J; Cui J
Front Cell Infect Microbiol; 2023; 13():1023948. PubMed ID: 37457958
[TBL] [Abstract][Full Text] [Related]
5. Activity of Cefiderocol, Ceftazidime-Avibactam, and Eravacycline against Carbapenem-Resistant Escherichia coli Isolates from the United States and International Sites in Relation to Clonal Background, Resistance Genes, Coresistance, and Region.
Johnston BD; Thuras P; Porter SB; Anacker M; VonBank B; Snippes Vagnone P; Witwer M; Castanheira M; Johnson JR
Antimicrob Agents Chemother; 2020 Sep; 64(10):. PubMed ID: 32718965
[TBL] [Abstract][Full Text] [Related]
6. Epidemiology and Genomic Characteristics of Bloodstream Infection Caused by Carbapenem-Resistant
Yu W; Shen P; Chen Y; Zhou K; Chi X; Xiao Y
Front Cell Infect Microbiol; 2022; 12():926209. PubMed ID: 35811669
[TBL] [Abstract][Full Text] [Related]
7. The Potential Use of Ceftazidime-Avibactam Against Carbapenem Resistant
Nasomsong W; Nulsopapon P; Changpradub D; Pongchaidecha M; Pungcharoenkijkul S; Juntanawiwat P; Simsiriporn W; Santimaleeworagun W
Drug Des Devel Ther; 2021; 15():3095-3104. PubMed ID: 34295150
[TBL] [Abstract][Full Text] [Related]
8. Time-Kill Evaluation of Antibiotic Combinations Containing Ceftazidime-Avibactam against Extensively Drug-Resistant Pseudomonas aeruginosa and Their Potential Role against Ceftazidime-Avibactam-Resistant Isolates.
Montero MM; Domene Ochoa S; López-Causapé C; Luque S; Sorlí L; Campillo N; López Montesinos I; Padilla E; Prim N; Angulo-Brunet A; Grau S; Oliver A; Horcajada JP
Microbiol Spectr; 2021 Sep; 9(1):e0058521. PubMed ID: 34319141
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Susceptibility Testing Methods for Aztreonam and Ceftazidime-Avibactam Combination Therapy on Extensively Drug-Resistant Gram-Negative Organisms.
Khan A; Erickson SG; Pettaway C; Arias CA; Miller WR; Bhatti MM
Antimicrob Agents Chemother; 2021 Oct; 65(11):e0084621. PubMed ID: 34424044
[TBL] [Abstract][Full Text] [Related]
10.
Kazmierczak KM; Bradford PA; Stone GG; de Jonge BLM; Sahm DF
Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30249690
[No Abstract] [Full Text] [Related]
11. In vitro activity of aztreonam-avibactam against Enterobacterales isolates collected in Latin America, Africa/Middle East, Asia, and Eurasia for the ATLAS Global Surveillance Program in 2019-2021.
Wise MG; Karlowsky JA; Mohamed N; Kamat S; Sahm DF
Eur J Clin Microbiol Infect Dis; 2023 Sep; 42(9):1135-1143. PubMed ID: 37526796
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing
Zhang W; Guo Y; Li J; Zhang Y; Yang Y; Dong D; Zhu D; He P; Hu F
Antimicrob Resist Infect Control; 2018; 7():142. PubMed ID: 30479755
[TBL] [Abstract][Full Text] [Related]
13. Molecular Characterization of Carbapenem-Nonsusceptible Enterobacterial Isolates Collected during a Prospective Interregional Survey in France and Susceptibility to the Novel Ceftazidime-Avibactam and Aztreonam-Avibactam Combinations.
Dupont H; Gaillot O; Goetgheluck AS; Plassart C; Emond JP; Lecuru M; Gaillard N; Derdouri S; Lemaire B; Girard de Courtilles M; Cattoir V; Mammeri H
Antimicrob Agents Chemother; 2016 Jan; 60(1):215-21. PubMed ID: 26482307
[TBL] [Abstract][Full Text] [Related]
14. Geographic patterns of global isolates of carbapenem-resistant Klebsiella pneumoniae and the activity of ceftazidime/avibactam, meropenem/vaborbactam, and comparators against these isolates: Results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2020.
Lee YL; Ko WC; Hsueh PR
Int J Antimicrob Agents; 2022; 60(5-6):106679. PubMed ID: 36241011
[TBL] [Abstract][Full Text] [Related]
15. New options for bloodstream infections caused by colistin- or ceftazidime/avibactam-resistant Klebsiella pneumoniae.
Yu W; Luo Q; Shen P; Chen Y; Xu H; Xiao Y; Qiu Y
Int J Antimicrob Agents; 2021 Dec; 58(6):106458. PubMed ID: 34706255
[TBL] [Abstract][Full Text] [Related]
16.
Yu F; Lv J; Niu S; Du H; Tang YW; Bonomo RA; Kreiswirth BN; Chen L
Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29891605
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Etest and broth microdilution for evaluating the susceptibility of Staphylococcus aureus and Streptococcus pneumoniae to ceftaroline and of carbapenem-resistant Enterobacterales and Pseudomonas aeruginosa to ceftazidime/avibactam.
Huang YT; Kuo YW; Teng LJ; Liao CH; Hsueh PR
J Glob Antimicrob Resist; 2021 Sep; 26():301-307. PubMed ID: 34303027
[TBL] [Abstract][Full Text] [Related]
18. Synergistic Activity of Imipenem in Combination with Ceftazidime/Avibactam or Avibactam against Non-MBL-Producing Extensively Drug-Resistant Pseudomonas aeruginosa.
Zhang Y; Zhao J; Han J; Fan Y; Xiong Z; Zou X; Li B; Liu X; Li Z; Lu B; Cao B
Microbiol Spectr; 2022 Apr; 10(2):e0274021. PubMed ID: 35315696
[TBL] [Abstract][Full Text] [Related]
19. Molecular Mechanisms Driving the
Li X; Ke H; Wu W; Tu Y; Zhou H; Yu Y
mSphere; 2021 Dec; 6(6):e0085921. PubMed ID: 34935448
[TBL] [Abstract][Full Text] [Related]
20. Assessing the in vitro activity of ceftazidime/avibactam and aztreonam among carbapenemase-producing Enterobacteriaceae: Defining the zone of hope.
Avery LM; Nicolau DP
Int J Antimicrob Agents; 2018 Nov; 52(5):688-691. PubMed ID: 30044946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
